Innovation and Commercialization from Concept to Consumer
Mosaigen is a global knowledge development organization specializing in the applied research, development and commercialization of science & technology. We focus our proprietary models and processes in the fields of healthcare, life sciences, nanotechnology, renewable energy and high-performance computing. We work directly in the Americas, Europe, Middle East and Asia with our intellectual capital teams to bring your ideas to market. Mosaigen also provides access to innovation capital through a wide variety of sources with very unique funding and commercialization models.
NEWS
* June 2021.
Mosaigen Founder, Dr. Neil Campbell adds Zapogen, Inc. to the list of portfolio companies under development. Zapogen's proprietary platform of bionanotechnology materials are being developed for the indicative fields of cardiovascular and oncology.
* May 2021. Mosaigen's portfolio company, RespaRx Technologies, has completed studies of its proprietary platform technologies centered around nanotechnology-based meshes that can purify both air and water and be used in industrial, medical, and retail applications.
* March 2021. Humanetix, Inc., a Mosaigen company, completes pre-clinical evaluations regarding the proprietary platform of the "Virtual Patient". The Virtual Patient provides a patient-specific therapeutic and diagnostic platform to model disease progression, treatment and predictive analytical outcomes modeling using advance cell and AI approaches.
Innovation and Intellectual Capital Workshops
Full range of consulting services to include company or group workshops on innovation processes and fundraising. Our process centered around the "Reverse Start-Up" models bring together proven methods from the market and combines them with proprietary models that leverage multiple potential exits from the same sets of assets. This unique and proprietary approach provides increased chances for commercial success and allows for a de-risking of commercial R&D projects while providing a highly capital-efficient set of operations.
1. Intellectual Capital
Providing proprietary and accretive assets for commercialization.
2. Human Capital
Bringing together successful and broadly experienced management, director & advisory boards, and consultants.
3. Financial Capital
Diverse sources of capital, both private and public options to drive the commercial potential and exit possibilities of the assets.
4. Operations Capital
Modular approaches in capital-efficient operations, both organic and outsourced models.
5. Partnership Capital
Creative partnership approaches to leveraging platform-based technologies.
Portfolio Companies
Therapeutics
-
Zapogen, Inc.
-
BioNaut Corporation.
Medical Devices
-
RespaRx Technologies
-
KEIS, Inc.
-
CardioMetrics, Plc.
Personalized Medicine
-
Humanetix, Inc.
-
Marrotech, Plc.
Biometric Security
-
HeartPrint Analytics
Start-up, Turnarounds, Secondary Asset Repositions
Our current portfolio of companies and projects span from ICT, AI, Healthtech and Life Sciences. We provide concept to marketed product services as well as provide management, boards and advisors into our companies and projects.